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ABSTRACT
Nonarteritic anterior ischemic optic neuropathy (NA-AION) is the most common nonglaucomatous optic
neuropathy in adults over 50 years of age. It is usually related to cardiovascular risk factors. The primary
objective of this study was to evaluate choroidal thickness in patients with chronic NA-AION, and the
secondary objective was to evaluate macular thickness in these patients. This cross-sectional study compared
two groups: group 1 included 20 eyes of 20 patients with chronic NA-AION, and group 2 included 31 eyes of
31 healthy controls. In both groups, the choroidal thickness was measured using the enhanced depth imaging
program of Heidelberg Spectralis optical coherence tomography (Heidelberg Engineering, Heidelberg,
Germany). The macular thickness was also measured using the automatic software of the same device. The
mean follow-up time after NA-AION in group 1 was 57.17 ± 26.92 months. The mean choroidal thickness of the
posterior pole was 244.38 ± 61.03mm in group 1 and 214.18 ± 65.97mm in group 2 (p= 0.004). The mean macular
thickness was higher in group 2. Macular thickness is reduced in eyes that had an episode of NA-AION,
whereas choroidal thickness is generally higher in these eyes when compared with normal eyes. The increase in
choroidal thickness may be due to a local dysfunction in vascular autoregulatory mechanisms, which may
predispose to ischemic phenomena.
Keywords: Choroidal thickness, enhanced depth imaging, macular thickness, nonarteritic anterior ischemic
optic neuropathy, optical coherence tomography
INTRODUCTION
Nonarteritic anterior ischaemic optic neuropathy
(NA-AION) is the second most common optic neur-
opathy in adults older than 50 years of age, after
glaucoma.1 The reported incidence is 2 to 10 cases per
100,000, affecting more commonly Caucasian
Europeans.2 Classically the patient presents with
acute, unilateral, painless visual loss that evolves
over several hours to days. The examination reveals
optic disc oedema, relative afferent pupillary defect,
dyschromatopsia, diminished light brightness and
contrast sensitivity, and inferior altitudinal visual
field defect (however, any region of the visual field
can be affected). Symptomless optic disc oedema may
precede visual loss in NA-AION and could constitute
the earliest sign of the disease.3 Ischaemia or
hypoperfusion of the optic nerve head at the level of
lamina cribrosa is the most widely accepted patho-
physiology of NA-AION, but the location of the
associated vasculopathy and mechanism of ischaemia
remain uncertain. The optic disc in these patients has,
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characteristically, a small or nonexistent physiological
cup and retinal nerve fibre crowding—disc at risk.4
A few weeks after the ischaemic event, optic disc
pallor supervenes as a result of ganglion cell
apoptosis.5,6
The choroid is part of the uveal tract and,
histologically, it is arranged in three layers of vessels
from the outer to the inner part of the choroid: the
Haller layer (large choroidal vessels), the Sattler layer
(medium-sized vessels), and the choriocapillaris.7,8
Its main function is to provide oxygen and nourish-
ment to the outer retina, retinal pigment epithelium
(RPE) and the prelaminar portion of the optic nerve.9
Therefore, choroidal vascular changes may be impli-
cated in retinal, pigment epithelium, or optic nerve
diseases.
Until recently, choroidal imaging was limited to
fluorescein angiography, indocyanine green angiog-
raphy, laser Doppler flowmetry, and high-resolution
ultrasonography, with marked restrictions in terms of
resolution and ability to differentiate structures. In
2008, Spaide and colleagues described a new method
called enhanced depth imaging spectral-domain
optical coherence tomography (EDI-OCT) that enables
in vivo cross-sectional imaging of the choroid.11,12
Since then, several studies evaluated choroidal thick-
ness (CT) in eye diseases such as central serous
chorioretinopathy (CSCR),10 myopic retinopathy,13
age-related macular degeneration (AMD),14 among
others.
The primary objective of this study is to evaluate
CT in patients with chronic NA-AION, and the
secondary objective is to evaluate macular thickness
in these patients, comparing both parameters with a
demographically similar control group.
MATERIALS AND METHODS
This cross-sectional case-control study was conducted
at Central Lisbon Hospital Center, a university-based
tertiary centre. Two groups of patients were enrolled
in the study: group 1: 20 eyes of 20 patients with
NA-AION; group 2: 31 eyes of 31 age-matched
controls with a best-corrected visual acuity higher
than or equal to 20/25, using a Snellen chart. All the
participants had a refractive error lower than ±6
dioptres of spherical equivalent. In phakic patients
with no prior refractive surgery, the most recent
manifest refraction was recorded. The preoperative
manifest refraction was used in patients who had
prior cataract or refractive surgery. Participants were
excluded if they had ocular hypertension, glaucoma,
diabetes mellitus, significant cataract (Lens Opacities
Classification System III grade 4 or more for any
criteria15), retinal disease, previous retinal laser photo-
coagulation or vitreoretinal surgery, and other optic
neuropathies except for NA-AION. Written, informed
consent was obtained from all subjects, and this
investigation adhered to the tenets of the Declaration
of Helsinki. Ethics Committee approval was obtained.
The diagnosis of NA-AION was based on the
following criteria: (1) history of sudden onset of visual
loss with absence of other ocular and neurological
diseases that might influence or explain the patient’s
visual symptoms; (2) optic nerve head oedema at
the onset and spontaneous resolution within 2 to
3 months; (3) absence of systemic symptoms of giant
cell arteritis, absence of a high erythrocyte sedimen-
tation rate (450 mm/hour) or a high C reactive
protein; (4) visual field defect consistent with
NA-AION; and (5) no clinical evidence of inflamma-
tory, demyelinating, or compressive causes of optic
neuropathy.16,17 Every patient was submitted to a
complete ophthalmological evaluation that included
visual acuity assessment, biomicroscopy, fundoscopy,
Goldmann applanation tonometry, and macular and
choroidal thickness measurement using OCT
Heidelberg Spectralis (Heidelberg Engineering,
Heidelberg, Germany). Macular thickness parameters
were automatically calculated by existing Heidelberg
OCT software (version 5.3.2). Choroidal imaging was
made using EDI-OCT. Twenty-five sections, each
comprising 100 averaged scans, were obtained in a
20  20 (5.8 mm 5.8 mm) square centred on the
fovea. The horizontal section going through the centre
of the fovea and the horizontal section located
1250 mm superior and inferior to the fovea were
used for CT measurements. The choroid was mea-
sured using the caliper function from the outer border
of the hyperreflective line corresponding to the RPE to
the inner scleral border. CT measurements were made
centrally (in the foveal meridian) and at 1500 mm in
the nasal and temporal directions. A total of nine CT
points were thus obtained in each eye (Figure 1). All
the measurements were made between 2 PM and 4 PM
by two ophthalmologists experienced in analysing
OCT images. Only one eye was included per subject.
In case of patients with bilateral disease, the eye with
the better image quality was selected.
The data were statistically analysed using SPSS for
Windows, version 20.0 (IBM SPSS, Armonk, NY,
USA). Student’s t test was performed to compare the
mean differences between continuous variables.
Correlations between tissue thickness (both macular
and choroidal) and follow-up time were determined
using Spearman’s correlation test. A p value of less
than 0.05 was deemed statistically significant. All the
results were expressed as mean ± standard deviation.
RESULTS
Of the 20 patients initially recruited with a diagnosis
of NA-AION, 2 were excluded due to the concomitant
diagnosis of diabetes mellitus. Thus, in group 1 we
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studied 18 eyes of 18 patients, 3 of them with
bilateral disease (where we included only 1 eye).
Twelve patients were female and six were male. The
mean age in this group was 65.25 ± 12.76 years, and
the mean spherical equivalent was 0.75 ± 1.62 diop-
tres. In group 2 (control), 3 eyes were excluded due to
the diagnosis of subclinical epiretinal membrane after
OCT examination, with 28 eyes qualifying for the
study. Twenty-three patients were female and five
were male. The mean age in this group was
69.95 ± 10.28 years and the mean spherical equivalent
was 0.76 ± 1.98 dioptres. The mean age (p= 0.051) and
spherical equivalent (p= 0.49) were not significantly
different between the two groups. Mean best-
corrected visual acuity was 0.36 ± 0.35 in group 1
and 0.95 ± 0.84 in group 2 (p50.001). One patient in
group 1 and two patients in group 2 were former
smokers, but there were no current smokers in
any of the study groups. The mean follow-up time
after the NA-AION in group 1 was 57.17 ± 26.92
months.
Mean central retinal thickness was
264.61 ± 32.92 mm in group 1 and 279.25 ± 26.62mm in
group 2 (p= 0.052); in the upper macular quadrants,
the mean thickness was 287.22 ± 47.24 mm in group 1
and 345.00 ± 37.08mm in group 2 (p50.001); in the
lower quadrants, the average thickness was
281.61 ± 49.17 mm in group 1 and 328.11 ± 38.02 mm in
group 2 (p50.001). Retinal thickness was higher in
group 2 (control) in all the locations studied, and these
differences were significantly different in the upper
and lower quadrants.
The average posterior pole CT was
244.38 ± 61.03 mm in group 1 and 214.18 ± 65.97 mm in
group 2 (p= 0.004). The mean CT in the horizontal
foveal section was 239.11 ± 50.84mm in group 1 and
215.39 ± 62.23 mm in group 2 (p= 0.092); the mean
thickness of the choroid in the upper quadrants was
253.99 ± 65.42 mm in group 1 and 223.38 ± 65.64 mm in
group 2 (p= 0.065), the mean thickness of the choroid
in the inferior quadrants was 240.04 ± 67.84 mm in
group 1 and 203.75 ± 70.69 mm in group 2 (p= 0.046).
There were statistically significant differences in the
average CT of the posterior pole and in the CT of the
lower quadrants, with higher values in group 1
(Figure 2).
A statistical association was found between chor-
oidal thickness and the time elapsed since the onset of
NA-AION (r= 0.456, p= 0.047) in group 1 (Figure 3).
However, no such association was detected between
FIGURE 1 EDI-OCT imaging in three horizontal sections of the posterior pole. The choroid was measured vertically from the outer
border of the hyperreflective line corresponding to the RPE to the inner scleral border. Choroidal thickness measurements were made
centrally (in the foveal meridian) and at 1500mm in the nasal and temporal directions.
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the follow-up time and macular thickness in this
group (p= 0.53).
DISCUSSION
This study demonstrates that there are changes in the
CT of patients with chronic NA-AION. In these
patients, the mean CT at the posterior pole is signifi-
cantly higher compared with demographically similar
controls. Macular thickness in turn is lower in patients
with chronic NA-AION, as has been demonstrated in
previous studies.18,19 The decrease in macular thick-
ness is the result of a reduction in the thickness of the
ganglion cell complex, which encompasses the retinal
nerve fibre layer, the ganglion cell layer, and the inner
plexiform layer. A recent study by Gonul et al.
demonstrated that macular ganglion cell complex
thickness was comparable to peripapillary nerve fibre
layer thickness for accessing ganglion cell loss in
patients with chronic NA-AION.20
The choroid has the highest blood flow per unit
weight of any tissue in the body.21 It has a key role in
the nutrition and homeostasis of the outer layers of
the retina and prelaminar portion of the optic nerve.9
Although it is not consensual, several studies suggest
the existence of autoregulation in choroidal blood
flow, intended to offset fluctuations in blood pressure
and intraocular pressure.22–24 Some of the proposed
vasoregulatory mechanisms are the nitric oxide,
endothelins, and the autonomic nervous system.25–27
However, such mechanisms appear to be incomplete
and labile. The choriocapillaris oxygen partial pres-
sure is so high that it seems likely that the choroidal
circulation is regulated by additional factors different
from those acting in other vascular beds.28 For
example, Houssier et al. showed that CD-36 is a
scavenger receptor expressed in the basal RPE.
CD-36–deficient mice failed to induce cyclooxygen-
ase-2 (COX-2) and subsequent vascular endothelial
growth factor (VEGF) synthesis at the level of the RPE
and developed progressive degeneration of the
choriocapillaris.29 The change in CT could thus be an
indirect sign of various retinal diseases, intrinsic
pathologies of the choroid, optic neuropathies,
or systemic microangiopathy. Since the advent of
EDI-OCT, it has been possible to measure CT with
very good interobserver,11 intervisit,30 and intersys-
tem31 reproducibility, despite the lack of automated
software.
A study with normal subjects with a mean age of
47.5 years has shown an average subfoveal thickness
of 280.23 mm.32 Besides, CT decreases towards the
periphery asymmetrically, being thinner nasally than
temporally, and thinner inferiorly than superiorly.33
Increasing age correlates significantly with decreasing
CT; in one study it was found to decrease 14 mm for
each decade of life.34 It also correlates inversely with
myopic spherical equivalent and axial length.
Subfoveal choroidal thickness was shown to decrease
15 mm for each dioptre increase in myopic spherical
equivalent and to decrease 22 mm per mm increase in
axial lengh.35 Moreover, subfoveal CT is, on average,
62 mm higher in men than women35 and has a
circadian variation, being slightly thicker at the end
of the day.36,37 Existing studies did not find a clear
relationship between CT and systemic arterial blood
pressure.37,38
Recently, we have witnessed a growing interest for
the study of the choroid in various retinal, choroidal,
or optic nerve pathologies. In the case of high myopia,
it was demonstrated that the choroid is thinner, with
higher refractive errors and lower visual acuity.13,39 In
CSCR, the choroid is thicker compared with normal
eyes and does not show the expected age-dependent
thinning.10 Kim et al. reported an increase in CT
associated with polypoidal choroidal vasculopathy
(PCV).40 AMD is another disease associated with
changes in choroidal circulation.41,42 However, studies
FIGURE 2 Mean choroidal thickness (in mm) in both groups.
FIGURE 3 Correlation between choroidal thickness (in mm) and
the time (in months) since the onset of NA-AION.
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with EDI-OCT failed to demonstrate a consistent
change in CT relative to normal eyes or a relationship
between CT and the severity or type of AMD.14,43 The
study of CT can also be useful in the follow-up of
posterior uveitis. In the case of Voght-Koyanagi-
Harada disease, for example, there is a significant
increase in subfoveal CT during the acute phase,
which gradually decreases in response to corticoster-
oids.44 In glaucomatous optic neuropathy, although
there is no absolute consensus, most studies found no
changes in CT in comparison with normal eyes.45
Likewise, the studies in diabetes mellitus present
contradictory results, but the study with the largest
sample (N= 3468) showed an increase of subfoveal CT
in patients with diabetes mellitus compared with
healthy controls. However, CT was not higher in the
presence of diabetic retinopathy compared with dia-
betic patients without retinopathy, nor did it correlate
significantly with the severity of the retinopathy.46
Similarly to what happens in diabetes mellitus,
PCV, and CSCR, this study demonstrated that in
chronic-phase NA-AION there is also an increase in
choroidal thickeness, compared with a control group
with similar demographic characteristics and spher-
ical equivalent. In the case of PCV and CSCR,
choroidal thickening is a primary manifestation of
the disease and may secondarily lead to clinical
manifestations such as subretinal oedema and macu-
lar detachment in the case of CSCR and subfoveal
choroidal neovascularization in the case of PCV.46
In NA-AION and diabetes mellitus–related choroidal
thickening, the clinic and pathological significance is
not so straightforward. In the particular case of
NA-AION, the primary pathophysiological phenom-
enon leading to ischaemia of the optic nerve head is
not completely understood.47 The optic nerve head is
supplied by an anastomotic arterial circle derived
from the short posterior ciliary arteries. Fluorescein
angiography studies provide indirect evidence that
circulatory insufficiency in the paraoptic branches of
the short posterior ciliary arteries is the primary cause
of the ischaemic event.47 However, no adequate
systematic histopathological study of these vessels
was able to demonstrate if it results from an athero-
sclerotic, thrombotic, or embolic phenomena.48 Levin
and Danesh-Meyer recently proposed that NA-AION
may be primarily a venous disease.49 Hayreh et al., on
the other hand, consider defective vascular autoregu-
lation as the primary pathophysiological event. This
abnormality would render some individuals more
susceptible to flow-reducing events, such as nocturnal
hypotension.50 This theory is supported by the fact
that nearly 75% of NA-AION occur during sleep.51
In our opinion, the increase in CT in patients with
chronic NA-AION is a marker of the local dysfunction
of the vascular autoregulation mechanisms, further
supporting this theory. The positive correlation
between CT and the time elapsed since the ischaemic
event suggests either two hypotheses. The first
hypothesis is that defective vascular autoregulation
could be a slowly progressive and cumulative pro-
cess. At some moment, the autoregulation mechan-
isms could become insufficient to compensate for a
hypotensive event, leading to NA-AION. Considering
these microvascular changes act as a continuum, we
hypothesise that a slight increase in CT could be
present for some time before the ischaemic event.
Another hypothesis is that the macular tissue, which
is decreased in these patients, could be relevant to the
underlying choroid. The decrease in metabolic activity
in that overlying retinal area could interfere with the
choroidal vascular regulation, by promoting an imbal-
ance in the vasoactive mediators. In fact, a number of
papers suggest an important cross-talk between the
metabolic activity of these two compartments.52–54
These two hypotheses could even be complementary.
Future prospective and multicentric studies should
evaluate CT in subjects at risk for NA-AION as well as
the CT in the contralateral eye of individuals who
have had an episode of NA-AION, in order to test a
hypothetical relationship between this parameter and
the future occurrence of NA-AION.
There are important limitations to this study. The
small sample size may have limited the identification
of statistically significant differences in CT and
macular thickness in all the quadrants analysed. The
spherical equivalent was determined in all partici-
pants but not axial length, which, as mentioned
before, has a greater influence in CT than the
refractive error. Systemic arterial hypertension and
the use of antihypertensive medication were not
considered exclusion criteria in this study. However,
as stated before, published studies did not find a clear
relationship between choroidal thickness and sys-
temic arterial blood pressure.37,38 Moreover, the mean
age is slightly higher in the control group, although
this difference was not statistically significant. Taking
into account the highly significant difference in the
mean CT of the posterior pole between the two groups
(p50.01), we believe that this fact does not comprom-
ise the major conclusions of this study. Given the
irregularity of the chorioscleral border, measuring CT
at isolated points is not the most accurate method to
investigate the choroid, as the measurements may be
affected by focal irregularities of this boundary. The
methodology adopted in this work—measurement of
CT at 9 points per eye—aims to reduce this error.
However, the measurement of choroidal volume55 or
the development of automatic software would cer-
tainly be better ways to study its anatomy.
In conclusion, this study was the first to demon-
strate an increase in CT in eyes with chronic
NA-AION. This finding may contribute to a better
understanding of the pathophysiology of a disease
that can have devastating consequences for visual
function. Future studies are needed to test the
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potential of this characteristic in the identification of
patients at risk and in the follow-up of patients with
NA-AION.
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